DC ChemicalsChemicals for Life Science
sales@dcchemicals.com

DC67601 · Updated 24 October 2026

Sanofi Lipid 15
Formulation & Performance

This edition organizes the previously reviewed, source-linked product record. It is not a new independent review of every paper or supporting file. Reported and calculated values retain their original labels.

Literature-reported formulation composition

Componentmol%Role
Sanofi Lipid 1549Ionizable lipid
Cholesterol39Sterol
DSPC10Helper phospholipid
DPG-PEG20002PEG lipid
Reported total100Source values retained
Formulation calculator unavailable. A calculation is not enabled where component molecular weights or a fixed molar recipe are unverified. 49:39:10:2 is the base recipe in Methods. It is not the complete final anti-CD8-targeted composition. DPG-PEG (C16 anchor) differs from DMG-PEG. N/P 4-6 is an optimization range, not a uniquely fixed final recipe. Obtain and verify the complete composition and component molecular weights before planning component quantities.
4-6 (reported optimization range)
65 mM acetate, pH 4; RNA 300 micrograms/mL in aqueous feed. Exchange into 1.5 mM HEPES pH 7.4 with 150 mM NaCl.
Reporter or CAR mRNA
Base formulation characterization; separate anti-CD8-targeted cell and mouse experiments
See individual targeted assay; no universal dose assigned
Human PBMCs and humanized mice in separate assays
NanoAssemblr Ignite/NxGen, 9 mL/min, aqueous:ethanol 3:1; diafiltration with 100 kDa regenerated-cellulose devices. The CAR platform additionally requires targeting-conjugate post-insertion.

Literature-reported performance for the cited formulation

Literature-reported86 nm; PDI 0.11Lipid15/DPG-PEG formulation, before targeting-conjugate post-insertionSI PDF p.38, Table S6
Literature-reported90 nm; PDI 0.12Separate Nb8 VHH post-insertion sample; freeze/thaw sample is 94 nm, PDI 0.11SI PDF p.38, Table S6
Literature Data DisclaimerAll formulation parameters and performance values shown in this section are derived from the cited publication and are provided for reference only. These results were obtained using the specific materials, formulation process, cargo, dose, analytical method, model and administration route described in that study. Unless otherwise stated, the data were not generated or independently verified by DC Chemicals. DC Chemicals supplies the lipid compound only and does not guarantee that customers will reproduce the reported LNP properties or biological performance.

The administration route shown above was used in the cited study and is not a clinical-use instruction or recommendation by DC Chemicals.
Cited literature for this formulation and performance datasetReprogramming CD22 CAR-T cells in vivo using CD8-targeted mRNA-LNPs to treat hematological malignancies. DOI: 10.1016/j.ymthe.2026.02.020 DOI: 10.1016/j.ymthe.2026.02.020
49:39:10:2 is the base recipe in Methods. It is not the complete final anti-CD8-targeted composition. DPG-PEG (C16 anchor) differs from DMG-PEG. N/P 4-6 is an optimization range, not a uniquely fixed final recipe.

Primary article